Davis R M Inc. grew its holdings in Danaher Co. (NYSE:DHR) by 0.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 408,410 shares of the conglomerate’s stock after purchasing an additional 2,199 shares during the period. Danaher makes up 1.5% of Davis R M Inc.’s portfolio, making the stock its 21st biggest position. Davis R M Inc.’s holdings in Danaher were worth $37,909,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Danaher by 1.3% in the second quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock valued at $3,501,206,000 after purchasing an additional 520,776 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Danaher by 3.2% in the second quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock valued at $3,308,239,000 after purchasing an additional 1,233,876 shares in the last quarter. FMR LLC lifted its holdings in shares of Danaher by 0.9% in the second quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock valued at $1,656,100,000 after purchasing an additional 183,183 shares in the last quarter. Parnassus Investments CA increased its stake in shares of Danaher by 0.3% in the third quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock worth $840,351,000 after acquiring an additional 29,381 shares during the last quarter. Finally, Flossbach Von Storch AG increased its stake in shares of Danaher by 17.2% in the third quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock worth $581,324,000 after acquiring an additional 994,902 shares during the last quarter. Institutional investors own 76.11% of the company’s stock.

Danaher Co. (DHR) traded up $0.80 during trading on Tuesday, reaching $99.39. 1,894,500 shares of the company’s stock traded hands, compared to its average volume of 2,517,444. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00. The firm has a market capitalization of $69,140.00, a P/E ratio of 29.58, a price-to-earnings-growth ratio of 2.15 and a beta of 1.03. Danaher Co. has a 52-week low of $78.97 and a 52-week high of $99.66.

Danaher (NYSE:DHR) last posted its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.05. The firm had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.87 earnings per share. equities research analysts forecast that Danaher Co. will post 3.99 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s payout ratio is 16.67%.

DHR has been the topic of a number of research reports. Citigroup upped their price target on shares of Danaher to $107.00 and gave the stock a “buy” rating in a research note on Friday, December 15th. Robert W. Baird reaffirmed a “buy” rating on shares of Danaher in a research note on Friday. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $83.00 price target on shares of Danaher in a research note on Tuesday, September 26th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $96.00 price target on shares of Danaher in a research note on Thursday, January 4th. Finally, Credit Suisse Group upped their price target on shares of Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. One analyst has rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $94.91.

In other Danaher news, Director Donald J. Ehrlich sold 10,578 shares of the stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total transaction of $960,693.96. Following the transaction, the director now directly owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Daniel Raskas sold 37,870 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. Insiders have sold 273,810 shares of company stock worth $25,218,813 over the last three months. Company insiders own 12.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2018/01/16/danaher-co-dhr-shares-bought-by-davis-r-m-inc.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.